secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2026-06-22T12:14:24+00:00
Accession:  0001193125-26-276738
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha completes REVEAL pivotal trial dosing; longer-term data shows durable functional gains in Rett syndrome
--------------------------------------------------------------------------------

- Completed dosing of 17 patients in REVEAL pivotal trial; topline 6-month interim data and FDA feedback expected 1H 2027.
- 100% of 12 REVEAL Part A patients gained/regained ≥1 developmental milestone by 12 months post-TSHA-102.
- No treatment-related SAEs or DLTs across 29 patients dosed as of June 2026 cutoff.
- 310 total functional gains observed ≥12 months post-treatment (~26 per patient) across core disease domains.
- ASPIRE trial enrollment exceeded; expects to dose 4th patient in July 2026; safety data to support BLA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/0001193125-26-276738-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312526276738/d20817d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-276738

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer